Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01730521
Other study ID # EK 2012-N-27
Secondary ID
Status Completed
Phase N/A
First received November 7, 2012
Last updated September 12, 2013
Start date October 2012
Est. completion date June 2013

Study information

Verified date September 2013
Source Swiss Federal Institute of Technology
Contact n/a
Is FDA regulated No
Health authority Switzerland: Laws and standards
Study type Observational

Clinical Trial Summary

Iron metabolism may undergo changes during exercise, with reductions in classical iron status markers due to a variety of postulated mechanism which include hemodilution, increased iron loss, hemolysis and increased iron storage in muscles. Furthermore, it has been reported that vigorous training increases hepcidin, a central regulatory peptide in iron metabolism. This increase has been ascribed to the presence of subclinical inflammation. Increased hepcidin levels may reduce iron bioavailability and iron incorporation in erythrocytes.

Twenty healthy men subjects will be recruited as subjects for this study. Subjects should be generally healthy, with no history of blood donation in the last 6 months, should weigh less than 85 Kg, and not take iron supplements and/or multivitamin supplements. Subjects should have familiarity to sports and running, but not currently (i.e. in the past 3 months) training for more than 1h per week on average.

The aim of this study is to measure an iron bioavailability during a resting and an exercise phase lasting approx. 14 days with training sessions on alternate days. Subjects will participate in both restign and exercising protocols and act as their own controls during the study. Iron bioavailability will be measured via the incorporation of stable isotopic labels 14 days after administration. To control for changes in blood volume during the course of the study, blood volume of the participating subjects will be measured before and after the exercise phase with the CO-rebreathing method.

Measurement of iron bioavailability and iron incorporation in a resting and exercising phase will allow determine if the increased level of hepcidin seen in in exercise will induce a lower iron bioavailability and iron incorporation during exercise.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date June 2013
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- men, Generally Healthy age between 18-50 years;

- BMI between 18-25;

- nonanemic (Hb < 120 g/L);

- no intake of vitamins and nutritional supplements;

- no recent blood donation (<4 months);

- no previous participation in studies with stable iron isotopes in the past.

Exclusion Criteria:

- Chronic diseases, Metabolic diseases, GI tract diseases (self reported)

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise (Running)
the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.

Locations

Country Name City State
Switzerland ETH Zürich Zürich

Sponsors (1)

Lead Sponsor Collaborator
Swiss Federal Institute of Technology

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Cercamondi CI, Egli IM, Ahouandjinou E, Dossa R, Zeder C, Salami L, Tjalsma H, Wiegerinck E, Tanno T, Hurrell RF, Hounhouigan J, Zimmermann MB. Afebrile Plasmodium falciparum parasitemia decreases absorption of fortification iron but does not affect systemic iron utilization: a double stable-isotope study in young Beninese women. Am J Clin Nutr. 2010 Dec;92(6):1385-92. doi: 10.3945/ajcn.2010.30051. Epub 2010 Oct 6. Erratum in: Am J Clin Nutr. 2015 Apr;101(4):894. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Hepcidin levels and inflammation markers (C-Reactive Protein, 1-Alpha acid glycoprotein) Up to 2 months No
Primary Iron bioavailability from Stable isotopic labels Up to 2 months No
Secondary Blood volume increase during exercise Up to 2 months No